Đang chuẩn bị liên kết để tải về tài liệu:
Questionnaire-based detection of immunerelated adverse events in cancer patients treated with PD-1/PD-L1 immune checkpoint inhibitors

Immune checkpoint inhibitors (ICI) have become standard treatment in different tumor entities. However, safe treatment with ICI targeting the PD-1/PD-L1 axis requires early detection of immune-related adverse events (irAE). |